All articles by Kezia Parkins
Kezia Parkins is the lead editor for Medical Device Network and Medical Technology Magazine. She is an experienced healthcare writer and editor with special interests in MedTech, clinical trials, patient centricity and global health equality.
Kezia Parkins
Magazine: is the metaverse the next frontier in clinical trials?
In this issue: Clinical trials in the metaverse, making LFTs sustainable, foreign direct investment in medical devices and the affordability of 3D printed organs.
Magazine: A choppy history of racial bias in oximetry
In this issue: Covid-19 has put bias in oximetry back in the spotlight, DCTs are helping break down barriers in women’s health trials, continuous flow manufacturing builds on hype, and more.
A choppy history of racial bias in oximetry
Covid-19 has put oximeters and their inability to accurately assess blood oxygen levels in people of colour back in the spotlight.
Women’s health clinical trials: breaking down barriers through decentralisation
Women tend to be harder to recruit for clinical trials due to socioeconomic factors. But decentralised study designs help ease barriers to participation.
Covid-19 spurred on the self-testing revolution
Thanks to Covid-19, self-testing has become a common practice. Throughout the next few years, experts believe that this will continue to gain prominence.
Is FDA LDT surveillance set to improve as VALID Act heads to resolution?
By hitching a ride on the Medical Device User Fee Amendments expiration, the VALID Act could pass this year.
UK’s first digital health training programme launches for NHS frontline staff
Developed by ORCHA and the NHS, the Digital Health Academy will be available to frontline staff to improve uptake of digital health tools.
Covid-19: Mental health app growth reveals unmet needs
Prescriptions for mental health apps rose during the pandemic. So did new apps for Covid advice and tracing, but there is still no app for long Covid.
IQVIA on AI’s potential to match patients to trials and improve trial diversity
Lucas Glass, vice-president of IQVIA’s analytics center of excellence talks matching patients to trials with AI and how the tech can improve patient diversity rather than hinder it.
The Theranos saga: a wake-up call for the lab-developed test market
Elizabeth Holmes was accused of conning investors and patients with her “breakthrough” blood tests, but the case may have helped highlight important holes in regulation.